Bermekimab

DRUG4 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Acne InversaDermatitis, AtopicHidradenitis SuppurativaSuppurative Hidradenitis

Phase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa

CompletedNCT04019041

Janssen Research & Development, LLCAcne Inversa, Hidradenitis Suppurativa, Suppurative Hidradenitis

Start: 2019-09-16End: 2020-11-17Updated: 2023-07-27

A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis

TerminatedNCT04791319

Janssen Research & Development, LLCDermatitis, Atopic

Start: 2021-05-03End: 2022-03-31Updated: 2023-03-01

A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa

TerminatedNCT04988308

Janssen Research & Development, LLCHidradenitis Suppurativa

Start: 2021-10-12End: 2022-11-23Updated: 2023-11-13

A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

TerminatedNCT04990440

Janssen Research & Development, LLCDermatitis, Atopic

Start: 2021-09-02End: 2022-03-09Updated: 2023-05-24

Related Papers

Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies.

2024-08-308 citations